BRTX-100 is the first and only stem cell product candidate cleared to be evaluated in the cervical degenerative disc disease ...

MELVILLE, N.Y., Feb. 27, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical ...

BRTX-100 is the first and only stem cell product candidate cleared to be evaluated in the cervical degenerative disc disease setting - - IND clearance expands Company's advanced clinical pipeline for ...

The pain can range from cervical intervertebral discs, facet joints to atlantoaxial joints. Cervical discogenic pain syndrome is a common source of neck pain with a reported prevalence between 16% to ...

MELVILLE, N.Y., Feb. 27, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) ...

The company is planning a Phase 2 study for BRTX-100, indicating progress in clinical development and commitment to addressing chronic cervical discogenic pain, which affects a large segment of ...

In the meantime, we continue to advance our FDA Fast Track-designated BRTX-100 chronic lumbar disc disease (cLDD) program.” 1 Saini A, Mukhdomi T. Cervical Discogenic Syndrome. 2023 Apr 3. In: ...

BioRestorative Therapies (BRTX) announced the U.S. Food and Drug Administration has cleared its Investigational New Drug application for ...

After hours: February 28 at 7:55:51 PM EST Loading Chart for BRTX ...